Pharmacologic SubstanceAmino Acid, Peptide, or Protein
nci:P108
Triptorelin
nci:P207
C0077275
nci:P210
57773-63-4
nci:P302
Palliative treatment prostate carcinoma
nci:P303
Breast cancer; Lupus; Prostate cancer
nci:P319
9081Y98W2V
nci:P322
FDA
nci:P325
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A drug that is used to treat advanced prostate cancer, and is being studied in the treatment of breast cancer. It belongs to the family of hormonal drugs called gonadotropin-releasing hormone analogs.</n0:def-definition><n0:def-source>NCI-GLOSS</n0:def-source></n0:ComplexDefinition>
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men. (NCI04)</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>